Glomerular Diseases

Glomerular Dis, DOI: 10.1159/000518404
Received: April 23, 2021
Accepted: July 8, 2021
Published online: July 13, 2021

Deconvolution of FSGS pathophysiology using transcriptomics techniques
Deleersnijder D, Van Craenenbroeck AH, Sprangers B

ISSN: (Print), eISSN: 2673-3633 (Online)
https://www.karger.com/GDZ
Glomerular Diseases

Disclaimer:
Accepted, unedited article not yet assigned to an issue. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to the content.

Copyright:
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

© The Author(s). Published by S. Karger AG, Basel
Review Article
Deconvolution of FSGS pathophysiology using transcriptomics techniques

Dries Deleersnijder, MD1,2; Amaryllis H Van Craenenbroeck, MD PhD2,3; Ben Sprangers, MD PhD1,2
1 Department of Microbiology, Immunology and Transplantation, Laboratory of Molecular Immunology, Rega Institute, KU Leuven, Leuven Belgium
2 Division of Nephrology, University Hospitals Leuven, Leuven, Belgium.
3 Department of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, KU Leuven, Leuven, Belgium

Short Title:
‘Transcriptomics in FSGS’

Corresponding author:
Full name: Prof. Dr. Ben Sprangers
Department: Department of Microbiology, Immunology and Transplantation, Laboratory of Molecular Immunology
Institute/University/Hospital: Rega Institute, KU Leuven
Division of Nephrology, University Hospitals Leuven
Street Name & Number: Herestraat 49, box 811
City, State, Postal code, Country: Leuven, 3000, Belgium
Tel: +32 16 34 25 11
E-mail: ben.sprangers@uzleuven.be

Number of Tables: 0 (main text), 2 (supplementary material)
Number of Figures: 2
Word count: 4,901 words
Keywords: transcriptomics, single-cell transcriptomics, focal segmental glomerulosclerosis, FSGS, biomarker
Abstract

Background:
Focal segmental glomerulosclerosis (FSGS) is a histopathological pattern of renal injury and comprises of a heterogeneous group of clinical conditions with different pathophysiology, clinical course, prognosis and treatment. Nevertheless, subtype differentiation in clinical practice often remains challenging, and we currently lack reliable diagnostic, prognostic and therapeutic biomarkers. The advent of new transcriptomics techniques in kidney research poses great potential in the identification of gene-expression biomarkers that can be applied in clinical practice.

Summary:
Transcriptomics techniques have been completely revolutionized in the last two decades, with the evolution from low-throughput reverse transcription polymerase chain reaction (RT-PCR) and in situ hybridization (ISH) techniques to microarrays and next-generation sequencing techniques including RNA-sequencing (RNA-seq) and single-cell transcriptomics. The integration of human gene expression profiles with functional in vitro and in vivo experiments provides a deeper mechanistic insight into the candidate genes, which enables the development of novel targeted therapies. The correlation of gene expression profiles with clinical outcomes of large patient cohorts, allows for the development of clinically applicable biomarkers that can aid in diagnosis and predict prognosis and therapy response. Finally, the integration of transcriptomics with other ‘omics’ modalities creates a holistic view on disease pathophysiology.

Key messages:
New transcriptomics techniques allow high-throughput gene expression profiling of patients with FSGS. The integration with clinical outcomes and fundamental mechanistic studies, enables the discovery of new clinically useful biomarkers that will finally improve the clinical outcome of patients with FSGS.
Introduction

Focal segmental glomerulosclerosis (FSGS) is a renal histopathological pattern of injury defined by the presence of segmental sclerosis in some glomeruli (i.e., ‘focal’) on light microscopy, and is therefore not a specified disease entity [1]. FSGS encompasses a notoriously heterogeneous group of clinical conditions, all characterized by podocyte damage and subsequent glomerular loss as the central pathophysiological event. This clinically results in proteinuria, nephrotic syndrome and progressive kidney function loss [1]. FSGS can be subdivided in primary, secondary and genetic forms with different outcomes and therapeutic options [1]. Primary FSGS is caused by an unidentified circulating permeability factor that causes sudden and generalized injury to podocytes, the visceral glomerular epithelial cells, and is typically treated with immunosuppressive therapy or plasmapheresis [1]. Primary FSGS is a severe disease with a grim prognosis: about 20-40% of patients will likely develop end-stage kidney disease (ESKD) after a mean follow-up period of 3-6 years [2,3]. Patients that receive a kidney transplant have a high risk of disease recurrence (20-40%) which can already occur a few days after transplantation [4]. Secondary FSGS results from glomerular hypertension, in which glomeruli are subjected to abnormal stress (‘maladaptive’ FSGS) [1]. The treatment of the maladaptive form is centered around unloading the pressure on the glomeruli with renin-angiotensin system (RAS) blockade [5]. In comparison with primary FSGS, prognosis is considerably better with fewer patients progressing to ESKD [1,3]. The genetic forms of FSGS result from mutations in the genes that encode for podocyte proteins (e.g., nephrin, podocin, CD2-associated protein, α-actinin-4) and are typically resistant to therapy [1]. Although FSGS remains a rare disease with current incidence rates in the US of 3.2 cases per 100,000 person-years, this rate has doubled over the past ten years [5]. Despite the heterogeneous etiology and prognosis of the different FSGS subtypes, the first clinical and histopathological presentation may be very similar [1]. Moreover, to date, there are no validated serum, urine or histopathological biomarkers that reliably discriminate primary from secondary and genetic forms. It is therefore often challenging to identify the correct FSGS subtype in daily clinical practice [1]. Importantly, a misclassification will lead to inappropriate and therefore ineffective and potentially harmful therapy. We lack prognostic biomarkers, despite the fact that some patients rapidly progress to ESKD, while others remain relatively stable on antiproteinuric therapy. Next, to date, no markers reliably predict whether the patient will benefit from immunosuppressive treatments such as corticosteroids. And finally, we currently lack targeted therapies to treat FSGS patients, because the underlying pathophysiological mechanisms are incompletely understood. Recently, ‘omics’ technologies have revolutionized kidney research, in which the whole genome, epigenome, transcriptome and proteome of disease entities are studied, instead of only a few candidate disease targets [6,7]. Transcriptomics techniques can detect differential gene expression in disease vs. healthy states which translates in altered protein expression. Transcriptomics techniques have undergone a true revolution from low-throughput reverse transcription polymerase chain reaction (RT-PCR) and in situ hybridization (ISH) techniques that detect only a few expressed genes to the current extremely high-throughput and performant single-cell and single-nucleus RNA-sequencing techniques, which can be validated with multiplex assays or used in a multimodal approach which simultaneously analyses other ‘omics’ from the same single-cells [7]. Therefore, analysis of the transcriptome of patients with different subtypes of FSGS poses great potential to identify the underlying pathophysiology and candidate biomarkers that can ultimately improve clinical care.

This review provides an introduction in transcriptomics analysis of disease models and human patients with FSGS. Next, we describe how fundamental and clinical approaches can translate preliminary gene expression profiles into candidate tissue, urine or blood biomarkers. The ideal biomarker correlates with clinical outcomes so that it can be used in clinical diagnosis, prognosis and prediction of treatment susceptibility, while a fundamental insight of the underlying disease pathway will enable the development of novel targeted treatments.

Elucidating pathophysiology through gene expression analysis
The transcriptome refers to the type and quantity of all RNA-based molecules that are present in the cell in a (patho-)physiological condition [8]. These RNA molecules consist of protein-coding messenger RNA (mRNA), and non-protein-coding RNA including microRNA (miRNA), ribosomal RNA and transfer RNA (tRNA) [9]. Most human cells express ~11,000–13,000 genes, of which approximately ~8,000 genes are ubiquitously expressed among different tissues and ~3,000–5,000 expressed genes exhibit a cell type-specific pattern [10,11]. This differential gene expression results in a different phenotype, representing distinct cell populations with their own behavior both in healthy and disease states. To understand cell responses in different diseases, gene expression (transcriptome) and protein expression (proteome) can both be studied [12]. Although both fields have been completely revolutionized in the past decade with transcriptome and proteome study at the single-cell level [7], this review focuses on the transcriptome as a tool to decipher the pathophysiology of kidney diseases and more specifically FSGS. Although the potential of (single-cell) transcriptomics in the analysis of kidney diseases is already established [6,13–15], the study of glomerular diseases is still lagging behind, with most gene expression data still originating from older and lower throughput techniques. This is certainly true for FSGS, as this is a rare glomerulopathy, which makes the acquisition and analysis of sufficient tissue material and rigorous validation of candidate transcriptional biomarkers quite challenging.

**In vitro and in vivo models of FSGS**

As the acquisition of kidney tissue from patients with FSGS is difficult, many research groups have used experimental in vitro and in vivo models to study the disease (Fig. 1). Several functional studies have used cultured human podocytes to study podocyte injury and cytoskeleton morphology in vitro, by modifying candidate genes implicated in cytoskeleton regulation [16–18], glomerular fibrosis [19], podocyte apoptosis [20], or by exposure to nephrotoxic agents (e.g., doxorubicin) [16]. However, the transcriptional profile and protein expression of in vitro podocytes differs substantially from podocytes in their native glomerular micro-environment, with loss of lineage-specific gene expression and phenotype, which limits the translation into human clinical practice [21,22]. Alternatively, various in vivo FSGS animal models have been used, created by the use of nephrotoxic agents, (partial) nephrectomy or genetic engineering (for a comprehensive overview, see Yang JW et al. [23]). In mice or rats, glomerular damage and FSGS-lesions can be induced by using toxic podocyte-damaging agents including doxorubicin/Adriamycin [16,18,24–29], puromycin aminonucleoside [18] and lipopolysaccharide (LPS) [27,29]. Resection of 5/6 of functional renal mass by nephrectomy (5/6 nephrectomy model) simulates human secondary FSGS due to a reduction in the number of functioning nephrons [23]. Genetic engineering of FSGS models include knockout mice for genes such as podocin (NPHS2) [30], COL4A3 (which is also associated with Alport syndrome) [31], C2DAP [32] and knock-in of ACTN4 mutations [33,34] or TRPC6 mutations [35], which are all associated with familial or sporadic genetic FSGS in humans [1]. Additionally, new candidate target genes (e.g., SRGAP1 [16], NEBL [18]) can be genetically altered in in vivo models to validate the role of these genes in disease pathophysiology [16–18,25].

**The challenge of obtaining human tissue of FSGS patients**

Candidate transcriptional disease targets or biomarkers identified in animal studies should be validated in human kidney tissue before clinical relevance can be claimed. In general, human kidney tissue for research is only available as two types of biopsy specimens: core needle biopsies and nephrectomy tissue (Fig. 1). While core needle biopsies are frequently performed in clinical practice, they yield little tissue material. More tissue can be acquired through partial or complete nephrectomy, but this is seldomly performed in patients with glomerular disease as the main indication is a renal mass. As a consequence, tissue from patients with FSGS is generally only available as core needle biopsies. While the identification and validation of disease targets or transcriptional tissue biomarkers requires many samples, this is generally not feasible in a single-center setting. To combat this shortcoming, many different multicenter initiatives and biobanks have been initiated. The Consortium of European Renal cDNA Bank (ERCB) - Kroener-Fresenius Biopsy
Bank was founded in the early years 2000 and is a collaboration of European research centers that collects kidney biopsy tissue for gene expression analysis in a predefined preservation and processing protocol [36], together with clinical information [6]. A second initiative, The Nephrotic Syndrome Study Network (NEPTUNE) is a multi-center collaborative consortium which unites research centers across the US and Canada to focus on translational research in patients with minimal change disease (MCD), FSGS and membranous nephropathy (MN) [37]. NEPTUNE has been running a prospective observational trial since 2010, which includes a biopsy cohort and a pediatric non-biopsy cohort and collects clinical data together with biological samples, including an additional research biopsy core during clinically indicated kidney biopsy in participants of the biopsy cohort [37]. The biopsy cohort has currently included more than 500 patients [38]. A more recent initiative, Cure Glomerulonephritis (CureGN), is also a multi-center initiative and prospective observational trial which aims to collect clinicopathological data from a total of 2400 patients with biopsy-proven MCD, FSGS, MN, or IgAN (including IgA vasculitis) across research centers in the US, Canada and Europe since 2014 [38]. Contrary to the biological samples obtained in the NEPTUNE trial, this study only collects blood and urine samples and no additional kidney biopsy tissue. CureGN is designed to include new patients, but also to complement and extend follow-up of NEPTUNE participants, which will allow better correlation of their molecular profile with long-term clinical outcome data [38]. The cohort identified in CureGN will also be used for validation studies of identified candidate blood and/or urine biomarkers [38]. Many other smaller registries exist, which can also function as independent validation cohorts [38]. In conclusion, these large registries allow the compilation of sufficient patients with FSGS to study their molecular transcriptomic profile in kidney tissue, blood and urine, and allow correlation with histopathological and long-term clinical outcome data to identify and validate new biomarkers that can be applied in clinical practice.

How to study the transcriptional profile of human FSGS patients

The aforementioned multicenter initiatives are very promising to the research field of transcriptomic profiling in FSGS. Indeed, several studies have already used samples from FSGS patients derived from ERCB [22,39–44] or NEPTUNE [41,42,44,45]. Most of them used microarrays, although recently next-generation sequencing techniques such as bulk RNA-seq have also been used [44,46]. However, the first single-cell transcriptomics study on kidney tissue of FSGS patients is yet to be published. Published transcriptomics datasets of kidney disease including FSGS are also easily accessible online, at different repositories or through the search engine and data mining tool ‘Nephroseq’ (available at www.nephroseq.org, formerly known as ‘Nephromine’ [47]). These datasets can be used to validate a candidate transcriptional biomarker or signature that was identified in in vivo or in vitro experiments [16,18,20,31,48–50] or in an independent human FSGS cohort. Vice versa, these datasets can first be ‘mined’ for potential disease targets or biomarkers, that could subsequently be studied in in vivo or in vitro models (typically FSGS mouse or rat models or cultured podocytes) or validated with transcriptomics or proteomics (e.g., immunohistochemistry) in independent cohorts to elucidate their role in disease pathophysiology [25]. Here, we systematically outline the major findings of the transcriptomics studies that have analyzed the gene expression profile of kidney tissue in human patients with FSGS (Fig. 1, Supplemental Tables 1-2).

1. Studies using RT-PCR and in situ hybridization

The earliest techniques to study gene expression include RT-PCR and in situ hybridization. In these low-throughput techniques, only a few target genes can be studied, and oligonucleotide sequences of the targeted transcripts should be known in order to choose the correct PCR-primers or hybridization-probes, respectively. Indeed, the first studies that analyzed gene expression in human kidney biopsies of FSGS patients with these techniques studied only a few candidate genes (Supplemental Table 1). Studies were done on snap-frozen or formalin-fixed paraffin-embedded (FFPE) tissue and mostly involved analysis of unprocessed biopsy cores, while some used microdissected glomeruli [51–54]. Upregulated genes in FSGS patients were primarily involved in inflammation (e.g., leukotriene metabolism [55], leukocyte infiltration [56,57], upregulation of
nuclear factor-κB [58], cytotoxic T-cell mediators [59]), cell proliferation (e.g., upregulation of proto-oncogens [60]) or fibrosis (e.g., genes involved in TGFβ-pathway [59,61]). Downregulated genes were primarily involved in the podocyte slit-diaphragms (e.g., nephrin [51,54], podocalyxin [54]). These studies identified important pathways involved in FSGS pathophysiology that were the focus of later research (e.g., TGFβ-pathway, apoptosis, gene regulation of podocyte-specific proteins). Later transcriptomics studies have used more high-throughput methods (microarray and RNA-seq), but still utilize RT-PCR and ISH to validate the expression of candidate marker genes or use ISH to spatially localize gene expression.

2. Studies using microarrays
Similar to PCR and ISH, microarrays also depend upon existing knowledge of the oligonucleotide sequence of the transcripts of interest [8]. In this technology, fluorescently-labelled cDNA is created from RNA from the sample and is subsequently hybridized to thousands of gene-specific complementary oligonucleotide probe-sets that are aligned on a high-density microarray [6,8,62]. When compared to RT-PCR and ISH, micro-arrays have a much higher throughput, as they simultaneously detect thousands of genes and enable the identification of gene expression profiles or ‘signatures’ [62]. As freezing of tissue is a conventional way of RNA preservation, either snap-frozen (stored at -80°C) or tissue conserved in RNase inhibitor (stored at -20°C, implemented in the protocol of ERCB [36] was used in microarray studies [6]. One study compared microdissected glomeruli from FFPE kidney tissue to frozen tissue. Despite reduced RNA quality in FFPE tissue, gene expression profiles of both sample types were highly correlated, making FFPE tissue a reasonable alternative to frozen tissue [63]. The first microarray studies were exploratory, and identified a general FSGS tissue fingerprint of many differentially expressed genes (Supplemental Table 2) [63–65]. These differentially expressed genes were primarily involved in TGF-β signaling and fibrosis [63–65], apoptosis [64], podocyte specific genes involved in the slit diaphragms and possibly foot process effacement (FPE) [63–65]. With this approach, it is challenging to elucidate the pathophysiological role or specificity of certain significantly up- or downregulated genes. Therefore, later studies were more hypothesis-driven, implementing transcriptomics in a few different approaches.

In a first approach, candidate genes or gene signatures from a large transcriptomics dataset are explored in depth, with correlation in animal models and in vitro experiments to gain fundamental mechanistic insight in the underlying pathophysiology (Fig. 2). [25,39,40,43,66,67] For example, two research groups found upregulation of genes involved in the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway and parietal epithelial cell (PEC) activation in kidney tissue of FSGS patients, which is associated with podocyte hypertrophy and glomerulosclerosis [43,68]. Both groups created a transgenic mouse model with mTORC1 hyperactivation in podocytes, which resulted in excessive podocyte hypertrophy, podocyte loss and development of FSGS-lesions [43,68]. Surprisingly, however, complete genetic podocyte-specific mTORC1-inhibition in a mouse model with active podocyte loss also resulted in disease progression, while partial genetic mTORC1-inhibition resulted in amelioration of disease progression, which suggests that moderate mTORC-inhibition might be beneficial [68]. Both research groups also used pharmacological mTORC1-inhibition in FSGS mouse models with active podocyte loss, which yielded conflicting results. The first study found a protective role of pharmacological mTORC1-inhibition with amelioration of disease progression [68], while the second study found exacerbated disease [43]. Therefore, it is hypothesized that mTOR-mediated podocyte hypertrophy is initially an adaptive protective response, until a critical threshold is reached and hypertrophy itself becomes maladaptive and leads to podocyte detachment [43]. This might suggest that mTOR-inhibition in FSGS has a therapeutic window and might be beneficial in these cases where podocyte hypertrophy is no longer protective but leads to podocyte loss [43,68]. This hypothesis remains to be validated and future studies should focus on early vs. late introduction of mTOR-inhibition and the use of different inhibitors and dosing strategies. Other mechanistic studies that analyzed possible human disease targets in in vivo models identified versican 1 and RARRES1 as possible tissue biomarkers in FSGS patients [25,67]. Versican 1 (a tubular cell-derived extracellular matrix protein) is upregulated in tubular cells of FSGS patients, which leads to fibroblast
activation, collagen synthesis and also correlates with renal function decline and fibrosis [67].

Upregulation of RARRES1 (a retinoic acid-related gene largely restricted to podocytes) in FSGS patients contributes to podocyte apoptosis and is also correlated with renal function decline [25].

One final example nicely illustrates how mechanistic insights in differentially expressed genes may indeed point to new possible targeted treatments. The research group of Wilkening et al. found upregulation of both C–C motif chemokine ligand 2 (CCL2) and its receptor C–C chemokine receptor type 2 (CCR2) in glomeruli of patients with FSGS, which play an important role in the pathophysiology of glomerulosclerosis through CCL2-mediated recruitment of CCR2-positive kidney macrophages.[69]

Next, CCL2 was shown to be also upregulated in glomeruli of mice that were treated with adriamycin and developed glomerulosclerotic lesions. Finally, transgenic mice deficient in CCR2-expression were treated with adriamycin and developed significantly less albuminuria, less inflammation and less glomerulosclerosis when compared to wild type mice, proposing CCR2-inhibitors as a potential therapy in FSGS. In fact, currently three trials are running that will evaluate the effect of CCR2-inhibitors in human patients with FSGS.[70]

Vice versa, gene expression from in vivo and in vitro studies can be correlated with published transcriptomics datasets in humans (Fig. 2) [16,18,20,31,48–50]. For example, the gene expression signature of a transgenic rat model of FSGS based on podocyte-specific genetic mTORC1-inhibition correlated with gene expression of human FSGS patients [50]. Another study found a CKD-progression gene expression signature in COL4A3 /- knockout mice, and these upregulated mouse signature genes significantly overlapped with upregulated genes in human FSGS patients [31]. This study also identified vorinostat, a lysine deacetylase inhibitor, as a candidate drug treatment to prevent CKD-progression, which again illustrates the potential of these mechanistic studies in identifying new possible targeted treatments [31].

In an alternative more clinical approach, a validated gene expression signature that is highly correlated with clinical outcomes can be used as a diagnostic or prognostic tissue biomarker, even if the underlying pathophysiology of all the differentially expressed genes is incompletely understood (Fig. 2) [42,71,72]. For example, one study compared the gene expression profile of steroid-sensitive FSGS vs. steroid-resistant FSGS [72]. Ideally, such a ‘steroid-resistance’ signature should additionally be validated in larger cohorts to provide a prognostic transcriptional tissue biomarker, although the exact pathophysiology of all involved genes is not necessarily known. As upregulated JAK-STAT signaling is involved in many glomerular diseases, another research group created a STAT1 activity score which comprised of the composite expression of 17 genes [42]. Kidney tissue of FSGS patients showed higher scores when compared to healthy patients, and higher scores correlated with worse kidney function at baseline, increased proteinuria and a worse prognosis, which makes this STAT1 score a possible prognostic tool [42].

Ideally, both the fundamental and clinical approaches are combined, yielding a tissue, urine or blood biomarker of which the underlying pathophysiology is understood and can be targeted with new treatments, while also correlating with clinical outcomes so that it can be used in clinical diagnosis, prognosis and prediction of treatment susceptibility. One study identified epidermal growth factor (EGF) as such a promising biomarker for the ‘regenerative functional reserve’ of kidney tubules in CKD, as intrarenal EGF transcripts and urinary EGF protein concentrations correlated with kidney function at time of biopsy and higher values were associated with slower renal function decline [41].

This study first identified intrarenal transcripts that correlate with kidney function at time of biopsy, which identified EGF as such a potential candidate, because it shows kidney-specific expression in tubular cells and previous studies had already shown the anti-apoptotic and pro-proliferative effects of EGF on tubular cells [41]. Next, they confirmed that urinary EGF protein concentrations correlated with intrarenal EGF transcription and with renal function at time of biopsy and inversely correlated with renal function decline and interstitial fibrosis and tubular atrophy (IFTA) on biopsy, making this a potential non-invasive urinary biomarker to identify high-risk CKD patients with a poor prognosis [41].

3. Studies using RNA-seq
RNA-seq does not rely on probes that hybridize with known sequences of the transcripts of interest, as opposed to RT-PCR, ISH and microarrays. It is therefore an unbiased way of analysis, in which pre-existing knowledge of the oligonucleotide sequence of transcripts is not necessary [62]. Indeed, RNA-seq is considered an ‘open detection platform’ as it enables the detection of both known and new transcripts [62]. RNA-seq is also able to detect small oligonucleotide changes and transcript variants and has a wider detection range of gene expression levels when compared to microarrays, as it is more sensitive and does not have the problem of ‘saturation’ at high transcript levels [8,11,62]. Up until now, only two studies that use RNA-seq on kidney tissue of human FSGS patients have been published (Supplemental Table 2) [44,46]. The first study performed small RNA-seq to detect the differential expression of miRNAs in FSGS patients [46]. MicroRNAs are small non-coding RNA molecules that regulate gene expression on the post-transcriptional level by pairing with their target mRNA and promoting mRNA degradation or blockade of translation [73]. This study found upregulation of miR-21-5p in kidney tissue of FSGS patients, which suppresses PTEN, eventually leading to collagen deposition and fibrosis [46]. In the second study, Menon et al. proposed the expression of A2M, which encodes for α-2-macroglobulin and is a target gene of STAT1, as a new prognostic biomarker in FSGS, and exemplifies how large transcriptomics datasets can be boiled down to one clinically relevant candidate tissue biomarker [44]. This study first performed single-cell RNA-sequencing (scRNA-seq) of healthy kidney biopsy tissue. Next, they identified 78 genes that were exclusively expressed in glomerular endothelial cells (GECs) and created a composite GEC-score which was determined by the expression of these target genes. They interrogated bulk RNA-seq datasets of microdissected glomeruli of different glomerular diseases and found that FSGS patients had the highest GEC-score. Next, they divided the FSGS patients in two groups: one group with a relatively lower GEC score vs. another group with a higher score. The differential gene expression of group 1 vs. group 2 was compared and yielded A2M as a significantly differentially expressed target gene with higher expression in the second group. Finally, higher A2M expression correlated with worse prognosis, proposing A2M expression as a possible prognostic tissue biomarker in FSGS [44].

4. The power of single-cell transcriptomics

Microarrays and bulk RNA-seq generate a ‘transcriptional average’ of a group of cells, thereby losing information on the transcriptional profile of individual cells, which is undesirable in the analysis of the human kidney that consists of a highly specialized and differentiated cell population [14]. This problem is illustrated by the fact that several bulk transcriptomics studies of human FSGS patients have found downregulated podocyte-gene expression [27,51,54,63,65,71]: it remains unclear whether this represents true podocyte downregulation of these genes, or whether this observation is confounded by the fact that less podocytes are present in the sample due to podocyte loss in FSGS. To study the gene expression of individual cell populations, cell-sorting techniques such as fluorescence- or magnetic-activated cell sorting (FACS and MACS) can be used to enrich for a target cell population, in combination with ‘bulk’ transcriptomics techniques. However, this approach also averages the transcriptional profile of the sorted cell population and still does not reach single-cell resolution. Some computational techniques have been used to discover cell-lineage specific transcripts from microarray datasets, but again are unable to elucidate gene expression on the single-cell level [22]. In contrast, in situ hybridization techniques do reach single-cell resolution, but conventional low-throughput techniques can only profile a few genes per cell and are therefore not capable of detecting complex gene expression signatures. Recently, scRNA-seq and single-nucleus RNA-sequencing (snRNA-seq) have been developed, which are powerful new high-throughput techniques that are able to profile the gene expression of thousands of individual cells while retaining single-cell resolution [13,74]. In these techniques, biopsy tissue is mechanically and enzymatically dissociated into a viable single-cell suspension or single-nucleus suspension [75]. These individual cells or nuclei are captured with microfluidic devices into single-cell reaction vessels [75]. Most popular techniques are droplet-based (e.g., 10x Genomics Chromium Single Cell Gene Expression Solution [76], Drop-seq [77], inDrops [78]), in which single cells or nuclei are co-encapsulated with barcoded oligonucleotide primers and enzymes in
partitioning oil, although nanowells (e.g., Seq-Well [79], STRT-seq-2i [80]) or chip-based integrated fluidic circuits (IFCs, compatible with the C1 system by Fluidigm [81]) are used as well [75]. Cells or nuclei are subsequently lysed and mRNA is captured with oligonucleotide-primer mixes. Next, these transcripts are reverse transcribed with incorporation of barcoded single-cell information, amplified and sequenced. Downstream bioinformatic analysis is subsequently able to identify different cell types and cell states in a mixed population of cells, without prior knowledge of the identified cell types and markers [13,82]. ScRNA-seq and snRNA-seq have already been applied to healthy human kidneys [44,83–86], as well as kidney diseases including glomerular disease (lupus nephritis [87–89], IgA nephropathy [90], diabetic kidney disease [91]) and renal allografts [44,74,92]. Single-cell transcriptomics would be very useful in FSGS patients to identify the gene expression of individual glomerular cells and therefore solve the aforementioned problem of whether downregulated podocyte-genes in FSGS represent true downregulation on the single-podocyte level. Although very promising, some technical challenges arise when using single-cell transcriptomics to study glomerular diseases, as glomerular cells and especially podocytes are not easily identified in these single-cell transcriptomics experiments [93,94]. Indeed, kidney tissue of patients with FSGS is generally only available as core needle biopsies, which yields low cell amounts as starting material [74]. To date, only three scRNA-seq studies have been able to isolate podocytes from core needle biopsies, and absolute cell counts were very low [44,90,95]. This might be especially problematic for FSGS patients in which podocyte damage, hypertrophy and detachment are all hallmarks of disease [43], which potentially makes the isolation and identification of these abnormal podocytes in single-cell transcriptomics experiments more difficult. Fortunately, other cells from the glomerular microenvironment such as glomerular endothelial cells are more abundantly identified in scRNA-seq experiments [44]. Furthermore, microarrays from the tubulointerstitial compartments of FSGS patients have also shown differential gene expression [28,42,66], which can also be further explored on the single-cell level. When compared to scRNA-seq, snRNA-seq might be superior in detecting podocytes, because it uses stronger dissociation techniques which are more efficient in isolating difficult-to-dissociate cell types [94,96]. Indeed, all snRNA-seq studies on human kidneys were successful in identifying podocytes [74,86,91]. However, to date, no study has applied a snRNA-seq method to core needle biopsies of human kidneys, which is the only sample type available in FSGS patients [94]. The first single-cell transcriptomics studies on kidney tissue of FSGS patients are highly anticipated and will have to show whether current experimental pipelines are efficient enough to identify affected podocytes in FSGS. Ideally, patients with primary, secondary and genetic FSGS should be included and their gene expression compared, to help elucidate the differences in pathophysiology and guide identification of candidate diagnostic, prognostic and therapeutic markers in the different subtypes.

Recently, three studies have performed scRNA-seq on individual cells present in the urine [87,95,97] of which one study identified urinary podocytes, whose transcriptome was highly correlated with kidney podocytes [97]. This technique might be of interest in FSGS, as affected and detached podocytes might be detectable in the urine with this technique. However, the viability of these damaged and detached podocytes might be lower, and the transcriptional signature of FSGS might be obscured by transcriptional changes induced by the long travel of these individual cells through the entire nephron and urinary tract. Nevertheless, analysis of urinary cells including podocytes might help in the deconvolution of disease pathophysiology and might be a means to discover non-invasive urinary biomarkers.

Finally, many new (single-cell) ‘omics’ technologies enable the measurement of different cell modalities including the genome, epigenome, proteome and spatial context [7]. Some assays combine the measurement of several cell modalities in one pipeline, including the measurement of single-cell transcriptomes together with cell surface proteins (e.g., CITE-seq [98]), chromatin accessibility (e.g., sci-CAR [99], which combines snRNA-seq with sciATAC-seq [100]) or spatial context (e.g., spatially resolved transcriptomics with Slide-seq [101] and 10x Genomics Visium Spatial Gene Expression Solution [94,102]. In conclusion, the field of single-cell ‘omics’ is rapidly evolving and will create new insights in the underlying pathophysiology of FSGS and related glomerular diseases.
Conclusion
The field of transcriptomics has evolved massively since the first microarray study on kidney tissue of FSGS patients in 2004 [64]. Many multicenter initiatives have compiled large and well-defined FSGS cohorts, and recent next-generation sequencing and single-cell (multi-)omics technologies have enabled integrative analysis of disease pathophysiology at the single-cell level. These conditions set the stage for the development of diagnostic, prognostic and therapeutic biomarkers for FSGS patients, as well as more targeted therapies. We envision a near future in which RNA or protein biomarkers are used on kidney tissue, blood or urine of FSGS patients to reliably differentiate them into primary, secondary or genetic subtypes, predict their risk for rapid disease progression and their responsiveness to therapies. Finally, a deep understanding of FSGS disease pathophysiology will enable the development of targeted therapies, which will ultimately improve patient outcomes.
**Statements**

**Acknowledgements**
We would like to thank Albert Herelixka for designing the figures included in this publication.

**Conflict of Interest**
The Authors declare no conflict of interest.

**Funding Sources**
Dries Deleersnijder holds a PhD scholarship from the Special Research Fund KU Leuven, Belgium (grant number: DB/19/010/BM).
Ben Sprangers is a senior clinical investigator of The Research Foundation Flanders (F.W.O.) (grant number: 1842919N).

**Author Contributions**
DD, BS and AVC were responsible for the conception and design of the review. DD was responsible for data acquisition. DD, BS and AVC were responsible for analysis and interpretation of the data. DD, BS and AVC drafted the work and revised it critically for important intellectual content. DD, BS and AVC approved the published version of the manuscript. DD, BS and AVC agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
References

1 De Vriese AS, Sethi S, Nath KA, Glassock RJ, Fervenza FC. Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. J Am Soc Nephrol. 2018;29(3):759–74.

2 Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Focal and segmental glomerulosclerosis: Definition and relevance of a partial remission. J Am Soc Nephrol. 2005;16(4):1061–8.

3 Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity-related glomerulopathy: An emerging epidemic. Kidney Int. 2001;59(4):1498–509.

4 Choy BY, Chan TM, Lai KN. Recurrent Glomerulonephritis After Kidney Transplantation. Am J Transplant. 2006;6(11):2535–42.

5 Hommos MS, De Vriese AS, Alexander MP, Sethi S, Vaughan L, Zand L, et al. The Incidence of Primary vs Secondary Focal Segmental Glomerulosclerosis: A Clinicopathologic Study. Mayo Clin Proc. 2017;92(12):1772–81.

6 Schena FP, Nistor I, Curci C. Transcriptomics in kidney biopsy is an untapped resource for precision therapy in nephrology: A systematic review. Nephrol Dial Transplant. 2018;33(7):1094–102.

7 Stuart T, Satija R. Integrative single-cell analysis. Nat Rev Genet. 2019;20(5):257–72.

8 Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10(1):57–63.

9 Jiang S, Chuang PY, Liu ZH, He JC. The primary glomerulonephritides: A systems biology approach. Nat Rev Nephrol. 2013;9(9):500–12.

10 Wu Y, Zhang K. Tools for the analysis of high-dimensional single-cell RNA sequencing data. Nat Rev Nephrol. 2020;16(7):408–21.

11 Ramsköld D, Wang ET, Burge CB, Sandberg R. An abundance of ubiquitously expressed genes revealed by tissue transcriptome sequence data. PLoS Comput Biol. 2009;5(12):1–11.

12 Haque A, Engel J, Teichmann SA, Lönndberg T. A practical guide to single-cell RNA-sequencing for biomedical research and clinical applications. Genome Med. 2017;9(1):75.

13 Wilson PC, Humphreys BD. Single-cell genomics and gene editing: implications for nephrology. Nat Rev Nephrol. 2019;15(2):63–4.

14 Wu H, Humphreys BD. The promise of single-cell RNA sequencing for kidney disease investigation. Kidney Int. 2017;92(6):1334–42.

15 Wilson PC, Humphreys BD. Kidney and organoid single-cell transcriptomics: the end of the beginning. Pediatr Nephrol. 2020;35(2):191–7.

16 Rogg M, Maier JI, Dotzauer R, Artelt N, Kretz O, Helmstädt M, et al. SRGAP1 Controls Small Rho GTPases To Regulate Podocyte Foot Process Maintenance. J Am Soc Nephrol. 2021;32(3):563–79.

17 Artelt N, Ludwig TA, Rogge H, Kawandas P, Siegerist F, Blumenthal A, et al. The role of palladin in podocytes. J Am Soc Nephrol. 2018;29(6):1662–78.

18 Ge X, Zhang T, Yu X, Muwonge AN, Anandakrishnan N, Wong NJ, et al. LIM-Nebulette Reinforces Podocyte Structural Integrity by Linking Actin and Vimentin Filaments. J Am Soc Nephrol. 2020;31(10):2372–91.

19 Arif E, Solanki AK, Srivastava P, Rahman B, Tash BR, Holzman LB, et al. The motor protein Myo1c regulates transforming growth factor-β-signaling and fibrosis in podocytes. Kidney Int. 2019;96(1):139–58.

20 Liao M-C, Zhao X-P, Chang S-Y, Lo C-S, Chenier I, Takano T, et al. AT(2) R deficiency mediated podocyte loss via activation of ectopic hedgehog interacting protein (Hhip) gene expression. J Pathol. 2017;243(3):279–93.

21 Rinschen MM, Schroeter CB, Koehler S, Ising C, Schermer B, Kann M, et al. Quantitative deep mapping of the cultured podocyte proteome uncoverns shifts in proteostatic mechanisms during differentiation. Am J Physiol Physiol. 2016;311(3):C404–17.

22 Ju W, Greene CS, Eichinger F, Nair V, Hodgin JB, Bitzer M, et al. Defining cell-type specificity at the transcriptional level in human disease. Genome Res. 2013;23(11):1862–73.

23 Yang JW, Dettmar AK, Kronichler A, Gee HY, Saleem M, Kim SH, et al. Recent advances of animal model of focal segmental glomerulosclerosis. Clin Exp Nephrol. 2018;22(4):752–63.

24 Lee VW, Harris DC. Adriamycin nephropathy: A model of focal segmental glomerulosclerosis. Nephrology. 2011;16(1):30–8.
25 Chen A, Feng Y, Lai H, Ju W, Li Z, Li Y, et al. Soluble RARRES1 induces podocyte apoptosis to promote glomerular disease progression. J Clin Invest. 2020;130(10):5523–35.

26 Chung J-I, Goldstein L, Chen Y-JJ, Lee J, Webster JD, Roose-Girma M, et al. Single-Cell Transcriptome Profiling of the Kidney Glomerulus Identifies Key Cell Types and Reactions to Injury. J Am Soc Nephrol. 2020;31(10):2341–54.

27 Koehler S, Kuczkowski A, Kuehne L, Jüngst C, Hoehe M, Grahammer F, et al. Proteome analysis of isolated podocytes reveals stress responses in glomerular sclerosis. J Am Soc Nephrol. 2020;31(3):544–59.

28 Han R, Hu S, Qin W, Shi J, Hou Q, Wang X, et al. C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis. JCI Insight. 2019;4(7):e122912.

29 Boehm M, Bukosza EN, Huttery N, Herzog R, Aufricht C, Kraotchwill K, et al. A systems pharmacology workflow with experimental validation to assess the potential of anakinra for treatment of focal and segmental glomerulosclerosis. PLoS One. 2019;14(3):e0214332.

30 Mollet G, Ratelade J, Boyer O, Muda AO, Morisset L, Lavin TA, et al. Podocin inactivation in mature kidneys causes focal segmental glomerulosclerosis and nephrotic syndrome. J Am Soc Nephrol. 2009;20(10):2181–9.

31 Williams VR, Konvalinka A, Song X, Zhou X, John R, Pei Y, et al. Connectivity mapping of a chronic kidney disease progression signature identified lysine deacetylases as novel therapeutic targets. Kidney Int. 2020;98(1):116–32.

32 Shih NY, Li J, Karpitskii V, Nguyen A, Dustin ML, Kanagawa O, et al. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science (80–). 1999;286(5438):312–5.

33 Grgic I, Hofmeister AF, Genovese G, Bernhardy AJ, Sun H, Maarouf OH, et al. Discovery of new glomerular disease-relevant genes by translational profiling of podocytes in vivo. Kidney Int. 2014;86(6):1116–29.

34 Michaud J-I, Lemieux Li, Dubé M, Vanderhyden BC, Robertson SJ, Kennedy CRJ. Focal and segmental glomerulosclerosis in mice with podocyte-specific expression of mutant alpha-actinin-4. J Am Soc Nephrol. 2003;14(5):1200–11.

35 Krall P, Canales CP, Kairath P, Carmona-Mora P, Molina J, Carpio JD, et al. Podocyte-Specific Overexpression of Wild Type or Mutant Trpc6 in Mice Is Sufficient to Cause Glomerular Disease. PLoS One. 2010;5(9):e12859.

36 Cohen CD, Frach K, Schlöndorff D, Kretzler M. Quantitative gene expression analysis in renal biopsies: A novel protocol for a high-throughput multicenter application. Kidney Int. 2002;61(1):133–40.

37 Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PXK, Barisoni L, et al. Design of the nephrotic syndrome study network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int. 2013;83(4):749–56.

38 Mariani LH, Bombas AS, Canetta PA, Flessner MF, Helmut M, Hladunewich MA, et al. CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. Am J Kidney Dis. 2019;73(2):218–29.

39 Sanchez-Niño MD, Poveda J, Sanz AB, Mezzano S, Carrasco S, Fernandez-Fernandez B, et al. Fn14 in podocytes and proteinuric kidney disease. Biochim Biophys Acta - Mol Basis Dis. 2013;1832(12):2232–43.

40 Beeken M, Lindenmeyer MT, Blattnner SM, Radón V, Oh J, Meyer TN, et al. Alterations in the ubiquitin proteasome system in persistent but not reversible proteinuric diseases. J Am Soc Nephrol. 2014;25(11):2511–25.

41 Ju W, Nair V, Smith S, Zhu L, Shedden K, Song PXK, et al. Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci Transl Med. 2015;7(316):316ra193.

42 Tao J, Mariani L, Eddy S, Maeker H, Kambham N, Mehta K, et al. JAK-STAT signaling is activated in the kidney and peripheral blood cells of patients with focal segmental glomerulosclerosis. Kidney Int. 2018;94(4):795–808.

43 Puelles VG, van der Wolde JW, Wanner N, Scheppach MW, Cullen-McEwen LA, Bork T, et al. mTOR-mediated podocyte hypertrophy regulates glomerular integrity in mice and humans. JCI Insight. 2019;4(18):e99271.

44 Menon R, Otto EA, Hoover P, Eddy S, Mariani L, Godfrey B, et al. Single cell transcriptomics identifies focal segmental glomerulosclerosis remission endothelial biomarker. JCI Insight. 2020;5(6):e133267.

45 Sampson MG, Robertson CC, Martini S, Mariani LH, Lemley K V., Gillies CE, et al. Integrative genomics identifies novel associations with apol1 risk genotypes in black neptune subjects. J Am Soc Nephrol. 2016;27(3):814–23.

46 Baker MA, Davis SJ, Liu P, Pan X, Williams AM, Iczkowski KA, et al. Tissue-specific MicroRNA expression patterns in four types of kidney disease. J Am Soc Nephrol. 2017;28(10):2985–92.
Martini S, Eichinger F, Nair V, Kretzler M. Defining human diabetic nephropathy on the molecular level: Integration of transcriptomic profiles with biological knowledge. Rev Endocr Metab Disord. 2008;9(4):267–74.

Potter AS, Drake K, Brunskill EW, Potter SS. A bigenic mouse model of FSGS reveals perturbed pathways in podocytes, mesangial cells and endothelial cells. PLoS One. 2019;14(8):e0216261.

Bonse J, Wennmann DO, Kremerskothen J, Weide T, Michgehul T, Pavenstädt H, et al. Nuclear YAP localization as a key regulator of podocyte function. Cell Death Dis. 2018;9(9):850.

Nishizono R, Kikuchi M, Wang SQ, Chowdhury M, Nair V, Hartman J, et al. FSGS as an adaptive response to growth-induced podocyte stress. J Am Soc Nephrol. 2017;28(10):2931–45.

Kim BK, Hong HK, Kim JH, Lee HS. Differential expression of nephrin in acquired human proteinuric diseases. Am J Kidney Dis. 2002;40(7):964–73.

Koop K, Eikmans M, Baelde HJ, Kawachi H, De Heer E, Paul LC, et al. Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol. 2003;14(8):2063–71.

Gerth J, Cohen CD, Hopfer U, Lindenmeyer MT, Sommer M, Gröne HJ, et al. Collagen type VIII expression in human diabetic nephropathy. Eur J Clin Invest. 2007;37(10):767–73.

Gebeshuber CA, Kornauth C, Dong L, Sierig R, Seibler J, Reiss M, et al. Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1. Nat Med. 2013;19(4):481–7.

Menegatti E, Roccatello D, Fadden K, Piccoli G, De Rosa G, Sena LM, et al. Gene expression of 5-lipoxygenase and LTA4 hydrolase in renal tissue of nephrotic syndrome patients. Clin Exp Immunol. 1999;116(2):347–50.

Lan HY, Yang N, Nikolic-Paterson DJ, Yu XQ, Mu W, Isbel NM, et al. Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int. 2000;57(2):347–53.

Tyková I, Hrubá P, Maixnerová D, Girmánová E, Mrázová P, Straňavová L, et al. Molecular profiling in IgA nephropathy and focal and segmental glomerulosclerosis. Physiol Res. 2018;67(1):93–105.

Schachter AD, Streihlau J, Zurakowski D, Vasconcellos L, Kim YS, Zheng X, et al. Increased nuclear factor-kappaB and angiotensinogen gene expression in posttransplant recurrent focal segmental glomerulosclerosis. Transplantation. 2000;70(7):1107–10.

Streihlau J, Schachter AD, Pavlakis M, Singh A, Tejani A, Strom TB. Activated intrarenal transcription of CTL-effectors and TGF-beta1 in children with focal segmental glomerulosclerosis. Kidney Int. 2002;61(1):90–5.

Takeamura T, Okada M, Akano N, Murakami K, Hino S, Yagi K, et al. Proto-oncogene expression in human glomerular diseases. J Pathol. 1996;178(3):343–51.

Schramek H, Sarközi R, Lauterberg C, Kronbichler A, Pirklbauer M, Albrecht R, et al. Neuropilin-1 and neuropilin-2 are differentially expressed in human proteinuric nephropathies and cytokine-stimulated proximal tubular cells. Lab Investig. 2009;89(11):1304–16.

Byron SA, Van Keuren-Jensen KR, Engelthaler DM, Carpten JD, Craig DW. Translating RNA sequencing into clinical diagnostics: Opportunities and challenges. Nat Rev Genet. 2016;17(5):257–71.

Hodgin JB, Borczuk AC, Nasr SH, Markowitz GS, Nair V, Martini S, et al. A molecular profile of focal segmental glomerulosclerosis from formalin-fixed, paraffin-embedded tissue. Am J Pathol. 2010;177(4):1674–86.

Schwab K, Witte DP, Aronow BJ, Devarajan P, Steven Potter S, Patterson LT. Microarray analysis of focal segmental glomerulosclerosis. Am J Nephrol. 2004;24(4):438–47.

Bennett MR, Czech KA, Arend LJ, Witte DP, Devarajan P, Potter SS. Laser Capture Microdissection-Microarray Analysis of Focal Segmental Glomerulosclerosis Glomeruli. Nephron Exp Nephrol. 2007;107(1):e30–40.

Han R, Hu S, Qin W, Shi J, Zeng C, Bao H, et al. Upregulated long noncoding RNA LOC105375913 induces tubulointerstitial fibrosis in focal segmental glomerulosclerosis. Sci Rep. 2019;9(1):716.

Han R, Hu S, Qin W, Shi J, Hou Q, Wang X, et al. C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis. JCI Insight. 2019;4(7):e122912.

Zschiedrich S, Bork T, Liang W, Wanner N, Eulenburg K, Munder S, et al. Targeting mTOR Signaling Can Prevent the Progression of FSGS. J Am Soc Nephrol. 2017;28(7):2144–57.

Wilkening A, Krappe J, Műhe AM, Lindenmeyer MT, Eltrich N, Luckow B, et al. C-C chemokine receptor type 2 mediates glomerular injury and interstitial fibrosis in focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2020;35(2):227–39.
De Vriese AS, Wetzels JF, Glassock RJ, Sethi S, Fervenza FC. Therapeutic trials in adult FSGS: lessons learned and the road forward. Nat Rev Nephrol. 2021 DOI: 10.1038/s41581-021-00427-1

Tong J, Xie J, Ren H, Liu J, Zhang W, Wei C, et al. Comparison of Glomerular Transcriptome Profiles of Adult-Onset Steroid Sensitive Focal Segmental Glomerulosclerosis and Minimal Change Disease. PLoS One. 2015;10(11):e0140453.

Tong J, Xie J, Ren H, Liu J, Zhang W, Wei C, et al. Comparison of Glomerular Transcriptome Profiles of Adult-Onset Steroid Sensitive Focal Segmental Glomerulosclerosis and Minimal Change Disease. PLoS One. 2015;10(11):e0140453.

Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010;11(4):252–63.

Wu H, Malone AF, Donnelly EL, Kirita Y, Uchimura K, Ramakrishnan SM, et al. Single-Cell Transcriptomics of a Human Kidney Allograft Biopsy Specimen Defines a Diverse Inflammatory Response. J Am Soc Nephrol. 2018;29(8):2069–80.

Lafzi A, Moutinho C, Picelli S, Heyn H. Tutorial: guidelines for the experimental design of single-cell RNA sequencing studies. Nat Protoc. 2018;13(12):2742–57.
92 Malone AF, Wu H, Fronick C, Fulton R, Gaut JP, Humphreys BD. Harnessing Expressed Single Nucleotide Variation and Single Cell RNA Sequencing To Define Immune Cell Chimerism in the Rejecting Kidney Transplant. J Am Soc Nephrol. 2020;31(9):1977–86.
93 Fu J, Akat KM, Sun Z, Zhang W, Schlonorff D, Liu Z, et al. Single-cell RNA profiling of glomerular cells shows dynamic changes in experimental diabetic kidney disease. J Am Soc Nephrol. 2019;30(4):533–45.
94 Deleersnijder D, Callemeyn J, Arijs I, Naesens M, Van Craenenbroeck A, Lambrechts D, et al. Current Methodological Challenges of Single-Cell and Single-Nucleus RNA-Sequencing in Glomerular Diseases. J Am Soc Nephrol. 2021;ASN.2021020157.
95 Menon R, Otto EA, Sealfon R, Nair V, Wong AK, Theesfeld CL, et al. SARS-CoV-2 receptor networks in diabetic and COVID-19–associated kidney disease. Kidney Int. 2020;98(6):1502–18.
96 Wu H, Kirita Y, Donnelly EL, Humphreys BD. Advantages of Single-Nucleus over Single-Cell RNA Sequencing of Adult Kidney: Rare Cell Types and Novel Cell States Revealed in Fibrosis. J Am Soc Nephrol. 2018;30(1):23–32.
97 Abedini A, Zhu YO, Chatterjee S, Halasz G, Devalaraja-Narashimha K, Shrestha R, et al. Urinary Single-Cell Profiling Captures the Cellular Diversity of the Kidney. J Am Soc Nephrol. 2021;32(3):614–27.
98 Stoeckius M, Hafemeister C, Stephenson W, Houck-Loomis B, Chattopadhyay PK, Swerdlow H, et al. Simultaneous epitope and transcriptome measurement in single cells. Nat Methods. 2017;14(9):865–8.
99 Cao J, Cusanovich DA, Ramani V, Aghamirzaie D, Pliner HA, Hill AJ, et al. Joint profiling of chromatin accessibility and gene expression in thousands of single cells. Science. 2018;361(6409):1380–5.
100 Cusanovich DA, Daza R, Adey A, Pliner HA, Christiansen L, Gunderson KL, et al. Multiplex single-cell profiling of chromatin accessibility by combinatorial cellular indexing. Science (80- ). 2015;348(6237):910–4.
101 Rodrigues SG, Stickels RR, Goeva A, Martin CA, Murray E, Vanderburg CR, et al. Slide-seq: A scalable technology for measuring genome-wide expression at high spatial resolution. Science (80- ). 2019;363(6434):1463–7.
102 Ståhl PL, Salmén F, Vickovic S, Lundmark A, Navarro JF, Magnusson J, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science (80- ). 2016;353(6294):78–82.
Figure Legends

Fig. 1. Overview of transcriptomics analysis of disease models and human patients with FSGS

**Abbreviations**: ADR: adriamycin; PA: puromycin aminonucleoside; LPS: lipopolysaccharide; ERCB: The Consortium of European Renal cDNA Bank; NEPTUNE: The Nephrotic Syndrome Study Network; RT-PCR: reverse transcription polymerase chain reaction; (F)ISH: (fluorescence) in situ hybridization; scRNA-seq: single-cell RNA-sequencing; snRNA-seq: single-nucleus RNA-sequencing; (+): advantage; (-): disadvantage.

Fig. 2. Overview of fundamental and clinical approaches to identify FSGS biomarkers

Kidney tissue, blood and urine derived from FSGS patients can be used for molecular profiling of the transcriptome and other (single-cell) omics including the (epi-)genome, proteome and spatial information. The correlation of this molecular profile with clinicopathological outcomes and fundamental mechanistic insights from FSGS disease models yields clinically useful biomarkers and disease targets for novel targeted therapies.

**Abbreviations**: GFR: glomerular filtration rate; IFTA: interstitial fibrosis and tubular atrophy.
Patients with FSGS

- Blood
- Urine
- Tissue

**Clinical and histopathological outcomes**

- Kidney function (e.g., GFR)
- Proteinuria
- Histopathology (e.g., IFTA)

**Molecular profile**

- Transcriptomics
- Proteomics
- Metabolomics

**Biomarkers**

- Diagnostic markers
- Prognostic markers
- Therapeutic markers
- Targets for therapy

**Final aim: Improvement of patient outcomes**

**Validation of candidate genes**

**Models**

- Fundamental mechanistic insights

Correlation with clinical outcome

Correlation with gene expression